The estimated Net Worth of Robert J Bertolini is at least $3.06 Milión dollars as of 20 May 2020. Mr. Bertolini owns over 3,530 units of Bristol-Myers Squibb Co stock worth over $1,587,144 and over the last 14 years he sold BMY stock worth over $1,138,645. In addition, he makes $332,500 as Independent Director at Bristol-Myers Squibb Co.
Robert has made over 9 trades of the Bristol-Myers Squibb Co stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 3,530 units of BMY stock worth $184,584 on 20 May 2020.
The largest trade he's ever made was exercising 11,990 units of Bristol-Myers Squibb Co stock on 1 March 2017 worth over $453,342. On average, Robert trades about 1,222 units every 25 days since 2011. As of 20 May 2020 he still owns at least 32,664 units of Bristol-Myers Squibb Co stock.
You can see the complete history of Mr. Bertolini stock trades at the bottom of the page.
Robert J. Bertolini , CPA., is Independent Director of the Company. Mr. Bertolini served as President and Chief Financial Officer of Bausch & Lomb Incorporated until its acquisition by Valeant Pharmaceuticals (February 2013-August 2013) Executive Vice President and Chief Financial Officer at Schering Plough Corp. through its merger with Merck & Co., Inc. (November 2003-November 2009) with responsibility for tax, accounting and financial asset management Spent 20 years at PricewaterhouseCoopers LLP, ultimately leading its global pharmaceutical industry practice
As the Independent Director of Bristol-Myers Squibb Co, the total compensation of Robert Bertolini at Bristol-Myers Squibb Co is $332,500. There are 17 executives at Bristol-Myers Squibb Co getting paid more, with Giovanni Caforio having the highest compensation of $18,767,300.
Robert Bertolini is 58, he's been the Independent Director of Bristol-Myers Squibb Co since 2017. There are 14 older and 20 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.
Over the last 17 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius a Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include: